Research graph
References from Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors. Local targets link to admitted publications; unresolved targets remain external evidence.
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives
10.32074/1591-951x-213 · 2021 · External reference
Sarcoma care in the era of precision medicine
10.1111/joim.13717 · 2023 · External reference
Diagnostic Differences in Expert Second-Opinion Consultation Cases at a Tertiary Sarcoma Center
10.1155/2020/9810170 · 2020 · External reference
Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group
10.1097/sla.0000000000001447 · 2016 · External reference
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial
10.1016/s1470-2045(20)30446-0 · 2020 · External reference
Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma: EORTC-62092 Trial (STRASS) Versus Off-trial (STREXIT) Results
10.1097/sla.0000000000005492 · 2023 · External reference
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2)
10.1245/s10434-023-13500-9 · 2023 · External reference
Decision-making for palliative versus curative intent treatment of retroperitoneal sarcoma (RPS)
10.21037/cco.2018.08.05 · 2018 · External reference
10.3390/ijms20010170
10.3390/ijms20010170 · External reference
Radiation Therapy for Soft Tissue Sarcoma: Indications, Timing, Benefits, and Consequences
10.1016/j.suc.2022.04.001 · 2022 · External reference
A Postoperative Nomogram for Local Recurrence Risk in Extremity Soft Tissue Sarcomas after Limb-Sparing Surgery Without Adjuvant Radiation
10.1097/sla.0b013e3182367aa7 · 2012 · External reference
Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies
10.3390/jcm10061182 · 2021 · External reference
Management of Ewing sarcoma family of tumors: Current scenario and unmet need
10.5312/wjo.v7.i9.527 · 2016 · External reference
Optimizing Rhabdomyosarcoma Treatment in Adolescents and Young Adults
10.3390/cancers14092270 · 2022 · External reference
Adjuvant chemotherapy in resectable synovial sarcoma
10.1002/jso.24688 · 2017 · External reference
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
10.1016/s1470-2045(14)70063-4 · 2014 · External reference
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration
10.1016/s0140-6736(97)08165-8 · 1997 · External reference
Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial
10.1200/jco.2001.19.5.1238 · 2001 · External reference
Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group
10.1200/jco.2011.37.7218 · 2012 · External reference
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial
10.1016/j.ejca.2018.12.009 · 2019 · External reference
Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications
10.1177/1758834017705588 · 2017 · External reference
Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas
10.1016/s0360-3016(03)00186-x · 2003 · External reference
Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients
2022 · External reference
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial
10.1002/cncr.33895 · 2022 · External reference
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
10.1016/s1470-2045(17)30334-0 · 2017 · External reference
The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients
10.1016/j.ejca.2019.11.013 · 2020 · External reference
Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group
10.1016/j.ejca.2017.06.017 · 2017 · External reference
Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment
10.1245/s10434-009-0586-2 · 2009 · External reference
Sorafenib for Advanced and Refractory Desmoid Tumors
10.1056/nejmoa1805052 · 2018 · External reference
Pazopanib, a promising option for the treatment of aggressive fibromatosis
10.1097/cad.0000000000000474 · 2017 · External reference
Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial
10.1158/1078-0432.ccr-10-1177 · 2010 · External reference
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
10.1056/nejmoa2210140 · 2023 · External reference
Biology and Management of Dedifferentiated Liposarcoma: State of the Art and Perspectives
10.3390/jcm10153230 · 2021 · External reference
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
10.1200/jco.2012.46.5476 · 2013 · External reference
Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma
2019 · External reference
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
10.1016/s1470-2045(12)70474-6 · 2012 · External reference
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas
10.1200/jco.22.01285 · 2023 · External reference
Unresolved reference
External reference
The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
10.1158/2159-8290.cd-23-0153 · 2023 · External reference
10.1200/jco.2023.41.16_suppl.11554
10.1200/jco.2023.41.16_suppl.11554 · External reference
Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS
10.2217/fon-2022-1291 · 2023 · External reference
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
10.1158/1078-0432.ccr-21-1291 · 2022 · External reference
Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate – The impact of fibrosarcomatous transformation
10.1016/j.ejso.2017.03.011 · 2017 · External reference
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
10.1056/nejmoa2303383 · 2023 · External reference
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
10.1158/1078-0432.ccr-17-3766 · 2018 · External reference
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial
10.1016/s1470-2045(19)30215-3 · 2019 · External reference
Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect
10.1093/annonc/mdq644 · 2011 · External reference
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma
10.1634/theoncologist.2017-0161 · 2018 · External reference
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
10.1016/s1470-2045(19)30153-6 · 2019 · External reference
Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial
10.1200/jco.2020.38.15_suppl.11516 · 2020 · External reference
A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience
2014 · External reference
RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results
2023 · External reference
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study
10.1016/s1470-2045(19)30663-1 · 2019 · External reference
Pexidartinib for advanced tenosynovial giant cell tumor: results of the randomized phase 3 ENLIVEN study
10.1016/s0140-6736(19)30764-0 · 2019 · External reference
The MOTION study: a randomized, Phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor
2023 · External reference
Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor
10.1038/s41598-019-51211-y · 2019 · External reference
Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE
10.1016/j.ejca.2021.07.016 · 2021 · External reference
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
10.1056/nejmoa1704795 · 2017 · External reference
10.1016/s1470-2045(16)30392-8
10.1016/s1470-2045(16)30392-8 · External reference
Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
10.1093/annonc/mdw405 · 2016 · External reference
Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib
10.1097/cad.0000000000000994 · 2020 · External reference
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor
10.1002/cncr.26098 · 2011 · External reference
Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor
10.1159/000486623 · 2018 · External reference
Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950)
2019 · External reference
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
10.1200/jco.19.02492 · 2020 · External reference
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
10.1182/blood-2017-04-779405 · 2017 · External reference
A randomized, placebo-controlled, phase 2 trial of INBRX-109 in unresectable or metastatic conventional chondrosarcoma
2022 · External reference
Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma
10.1002/cncr.32515 · 2020 · External reference
Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis
2021 · External reference
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma
2023 · External reference
P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE)
2021 · External reference
Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
10.1186/s40425-019-0689-7 · 2019 · External reference
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
10.1136/jitc-2021-002990 · 2021 · External reference
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
10.1016/s1470-2045(19)30691-6 · 2020 · External reference
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
10.1056/nejmoa1714448 · 2018 · External reference
Selumetinib in Children with Inoperable Plexiform Neurofibromas
10.1056/nejmoa1912735 · 2020 · External reference
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
10.1016/j.annonc.2022.05.519 · 2022 · External reference
Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade
10.1158/1078-0432.ccr-20-1706 · 2020 · External reference
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
10.1002/cncr.28669 · 2014 · External reference
Relevant Trials Update in Sarcomas and Gastrointestinal Stromal Tumors: What Surgeons Should Know
10.1016/j.soc.2022.03.002 · 2022 · External reference
GIST tumors: Who should get imatinib and for how long?
10.1016/j.yasu.2014.05.014 · 2014 · External reference
Precision Oncology in Gastrointestinal Stromal Tumors
10.3390/curroncol30050351 · 2023 · External reference
Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity
10.1158/1078-0432.ccr-21-1221 · 2021 · External reference
Surgical Management of Germline Gastrointestinal Stromal Tumor
10.1245/s10434-023-13519-y · 2023 · External reference
Syndromic gastrointestinal stromal tumors
10.1186/s13053-016-0055-4 · 2016 · External reference
Adjuvant therapy in primary GIST: state-of-the-art
10.1093/annonc/mds198 · 2012 · External reference
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors
10.1001/jamaoncol.2020.2091 · 2020 · External reference
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial
10.1001/jama.2012.347 · 2012 · External reference
Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
10.3389/fonc.2021.672500 · 2021 · External reference
10.1200/jco.2008.17.4284
10.1200/jco.2008.17.4284 · 2008 · External reference
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
10.1016/s0140-6736(06)69446-4 · 2006 · External reference
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
10.1016/s0140-6736(12)61857-1 · 2013 · External reference
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
10.1016/s1470-2045(20)30168-6 · 2020 · External reference
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
10.1016/j.ejca.2021.07.010 · 2021 · External reference
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
10.1016/s1470-2045(20)30269-2 · 2020 · External reference
Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib
10.1016/j.annonc.2023.04.006 · 2023 · External reference
An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors
10.3389/fonc.2022.927587 · 2022 · External reference
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
10.1200/jco.22.00294 · 2022 · External reference
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
10.1200/jco.21.00217 · 2021 · External reference
Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE
2023 · External reference
Gastrointestinal stromal tumors in the setting of multiple tumor syndromes
10.1097/cco.0000000000000089 · 2014 · External reference
Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response
10.1158/1078-0432.ccr-21-2092 · 2022 · External reference
Unresolved reference
External reference
Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs
10.1038/s41586-019-1668-3 · 2019 · External reference
Unresolved reference
External reference
